<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04285372</url>
  </required_header>
  <id_info>
    <org_study_id>KISS</org_study_id>
    <nct_id>NCT04285372</nct_id>
  </id_info>
  <brief_title>Keep bIfurcation Single Stenting Simple</brief_title>
  <acronym>KISS</acronym>
  <official_title>A Randomized, Prospective, Post-market, Multicenter Study to Evaluate the Potential Benefit of Side Branch Ballooning, in the Setting of Single Stenting With Systematic Proximal Optimization Technique, in the Treatment of Bifurcation Lesion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ceric Sàrl</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ceric Sàrl</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      KISS study is an investigator-initiated, multi-centre, prospective, randomized (1:1),
      parallel, two-arm, non-inferiority trial aiming to compare two bifurcation PCI procedures for
      Side Branch protection
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the treatment of bifurcation lesion, the role of side branch intervention for improving
      the safety of Percutaneous Coronary Intervention (PCI), when MB is treated according to the
      Murray law with a Proximal Optimization Technique (POT), remains unclear.

      The KISS study will evaluate the non-inferiority of no side branch intervention versus side
      branch ballooning, in the setting of single stenting with systematic proximal optimization
      technique.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Periprocedural Myocardial infarction</measure>
    <time_frame>up to 48 hours post-procedure, up to 12 months</time_frame>
    <description>Rate of peri-procedural Myocardial Infarction (MI) at discharge or 48 hours post-procedure whichever comes first as judged by clinical evaluation in association with day-1 troponin evaluation using the ARC-2 definition</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical success (1)</measure>
    <time_frame>Intraoperative, up to 12 months</time_frame>
    <description>Deployment of main branch (MB) stent with &lt;20% residual stenosis and a patent side branch at end of procedure upon corelab analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical success (2)</measure>
    <time_frame>Intraoperative, up to 12 months</time_frame>
    <description>Total procedure time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical success (3)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Acute gain in main and side branches as measured with a dedicated quantitative coronary analysis (QCA) software</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical success (4)</measure>
    <time_frame>Intraoperative, up to 12 months</time_frame>
    <description>Fluoroscopy time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical success (5)</measure>
    <time_frame>Intraoperative, up to 12 months</time_frame>
    <description>Total radiation dose (air kerma)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical success (6)</measure>
    <time_frame>Intraoperative, up to 12 months</time_frame>
    <description>Total contrast dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical success (6)</measure>
    <time_frame>Intraoperative, up to 12 months</time_frame>
    <description>Need to cross over (any intervention on SB in the test arm or failure to intervene on the SB in the control arm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Failure (TLF)</measure>
    <time_frame>1 month and 12 months</time_frame>
    <description>Composite of:
Cardiac Death
Target vessel Myocardial Infarction
Clinically driven Target lesion revascularization (ci-TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR)</measure>
    <time_frame>1 month and 12 months</time_frame>
    <description>Main Branch &amp; Side Branch TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis:</measure>
    <time_frame>1 month and 12 months</time_frame>
    <description>Definite or Probable stent thrombosis (ARC-2 criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angina status</measure>
    <time_frame>1 month and 12 months</time_frame>
    <description>Angina status according to the Canadian Cardiovascular Society (CCS) classification (Grade 1 to 4)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">596</enrollment>
  <condition>Coronary Disease</condition>
  <arm_group>
    <arm_group_label>Test group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No intervention on the side branch in the context of percutaneous coronary intervention for the treatment of bifurcation lesion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Side branch protection: Ballooning or Kissing Balloon Technique, in the context of percutaneous coronary intervention for the treatment of bifurcation lesion</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Side branch protection/ballooning</intervention_name>
    <description>Side branch protection in the context of percutaneous coronary intervention for the treatment of bifurcation lesion</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>No side branch protection/ballooning</intervention_name>
    <description>No intervention on the side branch</description>
    <arm_group_label>Test group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Coronary artery disease requiring revascularization that is amenable to percutaneous
             coronary intervention (PCI)

          2. Any de novo Medina type bifurcation lesion with &gt;70% lesion in the main vessel by
             visual assessment except Medina 0,0,1 if the planned strategy does not include a main
             branch stenting

          3. Side branch diameter compatible with a PCI with stent implantation (≥ 2.25mm)

          4. Side branch requiring a protection wire according to operator evaluation

          5. Anatomy compatible with a proximal optimization technique

          6. Post main branch treatment (stenting then POT): Absence of side branch occlusion Or
             low flow associated with ongoing ischemia (either chest pain or ST changes)

          7. Male or female patient &gt;18 years old

        Exclusion Criteria:

          1. Acute myocardial infarction with ongoing ST-elevation

          2. Cardiogenic shock

          3. Requirement for ongoing hemodialysis

          4. Life-expectancy limited to &lt;12 months due to co-morbid condition

          5. Lesion involves the left main coronary artery

          6. Lesion requiring a double stenting

          7. Plan to treat &gt;1 other coronary vessel at the time of the index procedure

          8. Two lesions treated in the same session: unsuccessful PCI on the single non
             bifurcation lesion in a non-target vessel before the treatment of the target lesion.

          9. Chronic total occlusion of any target vessel

         10. Left ventricular ejection fraction &lt;20%

         11. Side branch TIMI Flow &lt;3

         12. Pre-dilatation of the Side Branch during the procedure prior to randomization

         13. Known allergy to Aspirin

         14. Known allergy to Clopidorel and Prasugrel and Ticagrelor

         15. Known allergy to stent drug elutant

         16. Known allergy to any other component of Onyx Resolute stent

         17. Ongoing participation in another investigational device or drug study

         18. Inability to provide informed consent

         19. Patients under judicial protection, tutorship or curatorship

         20. Pregnant and breast-feeding women or intention to become pregnant prior to completion
             of all follow-up procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernard CHEVALIER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICPS - Institut Cardiovasculaire Paris Sud</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valéry ELIE, PhD</last_name>
    <phone>+33.1.76.73.92.25</phone>
    <email>contact@cerc-europe.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laure MORSIANI, PhD</last_name>
    <phone>+33.1.76.73.92.36</phone>
    <email>contact@cerc-europe.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Timone Adultes</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Jacques Cartier ICPS</name>
      <address>
        <city>Massy</city>
        <zip>91300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique du Pont de chaume</name>
      <address>
        <city>Montauban</city>
        <zip>82000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nîmes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Claude Galien ICPS</name>
      <address>
        <city>Quincy-sous-Sénart</city>
        <zip>91480</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Hilaire</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse Rangueuil</name>
      <address>
        <city>Toulouse</city>
        <zip>31959</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita' Cattolica del Sacro Cuore</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico San Donato</name>
      <address>
        <city>San Donato</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Santa Cruz</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Cabuenes</name>
      <address>
        <city>Gijón</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUV Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital Newcastle Newcastle Upon Tyne, Tyne and Wear</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 21, 2020</study_first_submitted>
  <study_first_submitted_qc>February 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2020</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary disease</keyword>
  <keyword>Bifurcation lesion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

